Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Xilio Therapeutics, Inc.NASDAQ: XLO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $344K fell 30.8% year over year, behind the -18.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 6.5% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.

Context

  • Depreciation & amortization amounted to 3.5% of revenue in FY2025, down 22.4 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -30.8% toward the trailing-twelve-month pace of -18.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$344K+6.5% QoQ
Last fiscal yearDec 2025
$1.54M-6.3% YoY
LTMMar 2026
$1.39M-18.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.8%——
1 year-6.3%——
3-year CAGR-5.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
1.54M USD
Year-over-year change
-6.3%
4-year CAGR
+0.7%

Depreciation & Amortization vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's LTM Mar 2026 depreciation & amortization of $1.39M is the highest of the 4 companies compared; the peer median is $821K.
  • Its year-over-year change of -18.3% is the 3rd highest of 4, against a peer median of -17.4%.
  • Depreciation & amortization amounts to 2.6% of revenue for XLO, versus a peer median of 2.5%.
XLO Competitors Peer median
Depreciation & Amortization for XLO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XLOXilio Therapeutics, Inc.LTM Mar 2026$1.39M -18.3%-5.9%2.6%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$873K +7.1%+5.5%2.5%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$821K -17.4%+29.0%—
PDSBPDS Biotechnology CorporationLTM Mar 2026$16.38K -48.0%+533.2%—
Peer median (excluding XLO) $821K-17.4%+29.0%2.5%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0006.34M43.77M
Cost of Revenue1.5M0001.54M
Gross Profit(1.5M)006.34M42.23M
Gross Margin———100.0%96.5%
Research & Development51.19M59.2M52.14M41.21M56.04M
Selling, General & Admin22.36M29.95M27M24.78M29.71M
Operating Expenses73.55M89.15M79.13M66.93M84.21M
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
EBITDA(73.7M)(86.38M)(74.5M)(58M)(33.5M)
EBITDA Margin———-914.3%-76.5%
Operating Income(75.04M)(89.15M)(79.13M)(60.58M)(41.98M)
Operating Margin———-954.9%-95.9%
Interest Income6000003.4M
Interest Expense600K00100K0
Other Income / Expenses(756K)927K2.73M2.34M6.95M
Income Before Tax(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Pre-Tax Margin———-918.0%-80.1%
Income Tax Expense00000
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Net Margin———-918.0%-80.1%
EPS (Basic)(189.28)(45.08)(38.92)(15.26)(4.19)
EPS (Diluted)(189.28)(45.08)(38.92)(15.26)(4.19)
Weighted Avg Shares400.45K1.96M1.96M3.82M83.59M
Weighted Avg Shares (Diluted)400.45K1.96M1.96M3.82M83.59M

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.